Moleculin Biotech, Inc. (MBRX)

NASDAQ: MBRX · IEX Real-Time Price · USD
+0.020 (3.74%)
Feb 26, 2024, 1:16 PM EST - Market open

Company Description

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses.

Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.

The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies.

It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19.

The company was incorporated in 2015 and is headquartered in Houston, Texas.

Moleculin Biotech, Inc.
Moleculin Biotech logo
Country United States
Founded 2015
IPO Date Jun 2, 2016
Industry Biotechnology
Sector Healthcare
Employees 15
CEO Walter V. Klemp

Contact Details

5300 Memorial Drive, Suite 950
Houston, Texas 77007
United States
Phone 713-300-5160

Stock Details

Ticker Symbol MBRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001659617
CUSIP Number 60855D200
ISIN Number US60855D2009
Employer ID 47-4671997
SIC Code 2834

Key Executives

Name Position
Walter V. Klemp Founder, Chairman, President and Chief Executive Officer
Jonathan P. Foster CPA Executive Vice President and Chief Financial Officer
Dr. Donald H. Picker Ph.D. Chief Scientific Officer
Dr. Waldemar Priebe Ph.D. Co-Founder, Founding Scientist and Chairman of Scientific Advisory Board
Dr. Robert C. Shepard FACP, M.D. Chief Medical Officer of Annamycin
Dr. John Paul Waymack M.D., Sc.D. Senior Chief Medical Officer
Dr. Sandra L. Silberman M.D., Ph.D. Chief Medical Officer of New Products
Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D. European Chief Medical Officer
Jacqueline Northcut Consultant
Louis Ploth Jr. Independent Advisor

Latest SEC Filings

Date Type Title
Feb 22, 2024 8-K Current Report
Feb 16, 2024 424B3 Prospectus
Feb 15, 2024 8-K Current Report
Feb 14, 2024 8-K Current Report
Feb 14, 2024 8-K Current Report
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 12, 2024 EFFECT Notice of Effectiveness
Feb 2, 2024 S-1 General form for registration of securities under the Securities Act of 1933
Jan 24, 2024 8-K Current Report
Jan 16, 2024 DEF 14A Other definitive proxy statements